SSA
ADMA icon

Schonfeld Strategic Advisors’s ADMA Biologics ADMA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-330,148
Closed -$2.97M – 2565
2026
Q1 		$2.97M Buy
330,148
+291,978
+765% +$4.61M 0.02% 663
2025
Q4 		$696K Buy
+38,170
New +$643K ﹤0.01% 1264
2024
Q3 		– Sell
-14,896
Closed -$167K – 2000
2024
Q2 		$167K Buy
+14,896
New +$125K ﹤0.01% 1833
2023
Q3 		– Sell
-28,835
Closed -$106K – 1722
2023
Q2 		$106K Sell
28,835
-77,513
-73% -$287K ﹤0.01% 1716
2023
Q1 		$352K Sell
106,348
-255,765
-71% -$884K ﹤0.01% 1304
2022
Q4 		$1.4M Sell
362,113
-476,353
-57% -$1.47M 0.01% 981
2022
Q3 		$2.04M Sell
838,466
-220,175
-21% -$528K 0.02% 849
2022
Q2 		$2.1M Sell
1,058,641
-181,015
-15% -$356K 0.02% 732
2022
Q1 		$2.27M Buy
1,239,656
+558,972
+82% +$872K 0.02% 686
2021
Q4 		$960K Buy
680,684
+604,684
+796% +$795K 0.01% 969
2021
Q3 		$86K Sell
76,000
-365,873
-83% -$513K ﹤0.01% 1957
2021
Q2 		$707K Sell
441,873
-250,414
-36% -$441K 0.01% 1041
2021
Q1 		$1.22M Buy
692,287
+118,714
+21% +$272K 0.01% 818
2020
Q4 		$1.12M Sell
573,573
-158,150
-22% -$332K 0.02% 769
2020
Q3 		$1.75M Buy
731,723
+144,806
+25% +$397K 0.03% 540
2020
Q2 		$1.72M Sell
586,917
-136,510
-19% -$392K 0.04% 445
2020
Q1 		$2.08M Sell
723,427
-517,366
-42% -$1.79M 0.13% 191
2019
Q4 		$4.96M Sell
1,240,793
-329,615
-21% -$1.44M 0.12% 199
2019
Q3 		$6.99M Sell
1,570,408
-595,992
-28% -$2.49M 0.21% 133
2019
Q2 		$8.38M Buy
2,166,400
+1,941,400
+863% +$8.57M 0.3% 84
2019
Q1 		$853K Buy
+225,000
New +$795K 0.03% 545

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Schonfeld Strategic Advisors's ADMA Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 330,148 shares — an estimated $2.97M sold.

Schonfeld Strategic Advisors first reported a position in ADMA in Q1 2019 and held it in 21 quarters. The position peaked at $8.38M in Q2 2019. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 330,148 ADMA Biologics shares in Q2 2026, an estimated $2.97M.
  • Schonfeld Strategic Advisors first reported a position in ADMA Biologics in Q1 2019 and held it in 21 quarters.
  • Schonfeld Strategic Advisors's ADMA Biologics position peaked at $8.38M in Q2 2019.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.